Use of oral vancomycin in children with autoimmune liver disease: A single centre experience

Table 4 Biochemical response to oral vancomycin and Sclerosing Cholangitis Outcomes in Pediatrics index score of 12 patients with autoimmune liver disease treated with oral vancomycin

Patients/diagnosis	Age at OVT (yr)	AST (NV ≤ 45 U/L)				ALT (NV ≤ 45 U/L)				GGT (NV ≤ 50 U/L)				Response to OVT 1	SCOPE index score2		Time on OVT (mo)	OVT side-effect	Overall FU3 (mo)
		Before OVT	After OVT	TTN	Result	Before OVT	After OVT	TTN	Result	Before OVT	After OVT	TTN	Result		Before OVT	After OVT
AIH	5.4	212	39	4 mo	NV	147	17	6 mo	NV	73	22	6 mo	NV	Complete	3 low risk	0 low risk	99	None	113
AIH	11.8	251	31	2 mo	NV	359	39	9 mo	NV	26	34	8 mo	NV	Complete	3 low risk	0 low risk	72	None	73
ASC	16.8	98	47	3 mo	< 1.5 NV	140	70	4	< 1.5 NV	39	83	4	< 1.5 NV	Partial	8 high risk	8 high risk	16	None	26
ASC	4.8	86	28	7 d	NV	156	38	14 d	NV	84	44	14 d	NV	Complete	4 medium risk	1 low risk	37	None	39
ASC	13.1	60	14	1 mo	NV	365	38	3 mo	NV	68	27	4 mo	NV	Complete	5 medium risk	2 low risk	31	None	84
ASC	15.2	71	40	14 mo	NV	140	56	14 mo	< 1.5 NV	52	164	12 mo	-	None	6 high risk	6 high risk	6	None	68
ASC	17.4	113	65	1 mo	< 1.5 NV	205	141	1 mo	-	49	226	1 mo	-	None	6 high risk	4 medium risk	3	None	52
ASC	15	407	30	6 mo	NV	856	35	6 mo	NV	61	28	1 mo	NV	Complete	5 medium risk	2 low risk	40	None	49
ASC	17.3	102	37	2 mo	NV	111	36	2 mo	NV	135	82	5 mo	< 1.5 NV	Partial	6 high risk	4 medium risk	18	None	61
ASC	12.5	76	31	2 mo	NV	124	40	7 mo	NV	86; TX	42	6 mo	NV	Complete	5 medium risk	4 medium risk	47	None	135
ASC	13.9	123	155	-	-	165	154	-	-	165	1800	-	-	None	8 high risk	8 high risk	6	None	86; TX
ASC	13.2	141	135	-	-	156	180	-	-	71 mo (range 26-165)	136	-	-	None	7 high risk	7 high risk	4	None	165
Response to OVT					10/12 (83%)				9/12 (75%)				8/12 (67%)				Median: 34 (range 1-99)		71 (range 26-165)

¹Complete response is defined as “normalization of all three liver enzymes [aspartate aminotransferase (AST), alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT)]”, partial response as “AST, ALT or GGT levels decreasing to < 1.5 × ULN without reaching normal value”, and no response as “no significant changes in liver enzymes”.

²Sclerosing Cholangitis Outcomes in Pediatrics: Points 0-3: Low risk; Points 4-5: Medium risk; Points 6-11: High risk.

³Time from diagnosis to last follow up visit.

AIH: Autoimmune hepatitis; ASC: Autoimmune sclerosing cholangitis; OVT: Oral vancomycin treatment; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transferase; TTN: Time to normalize or to achieve the lowest value; NV: Normal value; FU: Follow up; SCOPE: Sclerosing Cholangitis Outcomes in Pediatrics.